Comparative Pharmacology
Head-to-head clinical analysis: PROCHLORPERAZINE versus THIORIDAZINE HYDROCHLORIDE INTENSOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PROCHLORPERAZINE versus THIORIDAZINE HYDROCHLORIDE INTENSOL.
PROCHLORPERAZINE vs THIORIDAZINE HYDROCHLORIDE INTENSOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Prochlorperazine is a phenothiazine antipsychotic that acts as a dopamine D2 receptor antagonist in the chemoreceptor trigger zone (CTZ) and at high doses in the mesolimbic system. It also has anticholinergic and antiemetic effects.
Thioridazine is a typical antipsychotic of the phenothiazine class. It blocks dopamine D2 receptors in the brain, particularly in the mesolimbic pathway, and also exhibits antagonism at alpha-adrenergic, histaminergic H1, and muscarinic M1 receptors.
5-10 mg IM/IV every 3-4 hours as needed; or 5-10 mg PO 3-4 times daily; or 25 mg PR twice daily. Maximum IM/IV: 40 mg/day; PO: 40 mg/day.
50 mg orally twice daily initially, titrated to 200-800 mg/day in divided doses. Maximum 800 mg/day.
None Documented
None Documented
Clinical Note
moderateProchlorperazine + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Fluticasone propionate."
Clinical Note
moderateProchlorperazine + Haloperidol
"The metabolism of Haloperidol can be decreased when combined with Prochlorperazine."
Clinical Note
moderateProchlorperazine + Methylphenidate
"The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Methylphenidate."
Clinical Note
moderateTerminal elimination half-life: 23-25 hours, with prolonged elimination in hepatic impairment.
Terminal elimination half-life ranges from 21 to 30 hours (mean 24 h). In elderly or patients with hepatic impairment, half-life may be prolonged. Requires multiple days to reach steady state.
Renal: 70-80% (as metabolites), Fecal: 20-30% (unchanged and metabolites), Biliary: 10-15% of dose excreted in bile.
Primarily hepatic metabolism with <1% excreted unchanged in urine; metabolites eliminated in bile and feces. Approx. 30–40% of a dose appears in urine as metabolites (mostly sulfoxides and side-chain oxidized products) and 50–60% in feces.
Category A/B
Category A/B
Typical Antipsychotic / Antiemetic
Typical Antipsychotic
Prochlorperazine + Quinagolide
"The therapeutic efficacy of Quinagolide can be decreased when used in combination with Prochlorperazine."